Canadian Manufacturing

Bayer sweetens Monsanto takeover bid, now offering US$62B

by Geir Moulson, The Associated Press   

Canadian Manufacturing
Environment Financing Operations Food & Beverage

German chemical firm ups bid for U.S.-based seed maker by $3 per share

BERLIN—German drug and chemicals firm Bayer has increased its offer for U.S. seed company Monsanto Co. by US$3 a share to $125 per share, saying the move followed several weeks of private talks between the pair.

A combination would create a company with a strong presence in the U.S., Europe and Asia.

Bayer did not reveal the new offer’s valuation of Monsanto as debt obligations will have changed since the previous offer in May, which valued the American company at $62 billion.

Monsanto, which is based in St. Louis, Missouri, rejected the initial offer as “incomplete and financially inadequate.”


Monsanto acknowledged receipt of the revised bid but said in a brief statement that it wouldn’t comment further until its board of directors has reviewed the offer. It didn’t say when that might be.

Following private talks over the past several weeks, Bayer said July 14 it has “comprehensively addressed” Monsanto’s concerns and that it “is prepared to make certain commitments to regulators, if required, to complete the proposed acquisition.”

It added that it is also offering a $1.5 billion “reverse antitrust break fee” to reflect its confidence in securing a successful deal.

“We are convinced that this transaction is the best opportunity available to provide Monsanto shareholders with highly attractive, immediate and certain value,” Bayer CEO Werner Baumann said in a statement. “Bayer is fully committed to pursuing this transaction.”

The German company said its offer “fully captures the intrinsic value of Monsanto.”

It said its revised offer is 40 per cent higher than Monsanto’s closing share price of $89.03 on May 9, the day before Bayer made a written proposal to Monsanto.

Monsanto shares were up 2.7 per cent at $103.83 in New York trading after Bayer’s announcement.


Stories continue below

Print this page

Related Stories